Synapse - Find an Expert

2639 Results

Phase II clinical experience with the proteasome inhibitor PS-341 in patients with indolent lymphomas

Meeting Abstract

O'Connor, O. A.; Moskowitz, C. H.; Wright, J. J.; Macgregor-Cortelli, B.; Straus, D.; Furst, D.; Horse-Grant, D.; Schenkein, D. P.; Zelenetz, A. D.
Blood (2002)

Fulltext@MSK | Save

Clone specific PCR detects clonal cells after radiation therapy for early stage gastric MALT lymphoma

Meeting Abstract

Noy, A.; Yahalom, J.; Zaretsky, L.; Brett, I.; Zelenetz, A. D.
Blood (2002)

Fulltext@MSK | Save

An analysis of accelerated full course chemotherapy followed by upfront high dose therapy (HDT) and autologous stem cell transplantation (ASCT) for patients with International Prognostic Index IV (IPI IV) aggressive NHL

Meeting Abstract

Moskowitz, C. H.; Kewalramani, T.; Donnelly, G.; Zelenetz, A. D.; Noy, A.; Rice, D.; Kuznetsov, M.; Straus, D.; Nimer, S. D.; Portlock, C. S.
Blood (2002)

Fulltext@MSK | Save

Similar outcomes for chemosensitive (CS) relapsed or primary refractory peripheral T-cell lymphoma (PTCL) and diffuse large B-cell lymphoma (DLBCL) treated with autologous transplantation (ASCT)

Meeting Abstract

Kewalramani, T.; Nimer, S. D.; Zelenetz, A. D.; Hamlin, P. A.; Horwitz, S.; Qin, J.; Malhotra, S.; Yahalom, J.; Moskowitz, C. H.
Blood (2002)

Fulltext@MSK | Save

Gemicitabine/vinorelbine - A well tolerated and effective regimen for patients with relapsed/refractory Hodgkin's disease (RD) who fail autologous stem cell transplantation (ASCT)

Meeting Abstract

Hamlin, P. A.; Kewalramani, T.; Schaindlin, P.; Moskowitz, C. H.
Blood (2002)

Fulltext@MSK | Save

Xenogeneic DNA immunization against CD20 elicits immune responses and confers modest tumor protection in a mouse model of lymphoma

Meeting Abstract

Palomba, M. L.; Roberts, W. K.; Scheinberg, D. A.; Houghton, A. N.
Blood (2002)

Fulltext@MSK | Save

Autologous transplantation (ASCT) with total body irradiation (TBI) based conditioning appears superior to chemotherapy only (Non-TBI) conditioning for patients with relapsed or primary refractory chemosensitive (CS) diffuse large B-cell lymphoma (DLBCL) who have no extranodal sits (ENS) of disease (dz)

Meeting Abstract

Kewalramani, T.; Moskowitz, C. H.; Zelenetz, A. D.; Malhotra, S.; Qin, J.; Yahalom, J.; Nimer, S. D.
Blood (2002)

Fulltext@MSK | Save

Patients with transformed low grade lymphoma attain durable responses following outpatient radioimmunotherapy with tositumomab and iodine I 131 tositumomab [Bexxar (R)]

Meeting Abstract

Zelenetz, A. D.; Saleh, M.; Vose, J.; Younes, A.; Kaminski, M. S.
Blood (2002)

Fulltext@MSK | Save

Bexxar (R) radioimmunotherapy produces a substantial number of durable complete responses in patents with multiply relapsed or refractory low grade or transformed love grade non-Hodgkin's lymphoma

Meeting Abstract

Kaminski, M. S.; Zelenetz, A.; Leonard, J.; Saleh, M.; Jain, V.
Blood (2002)

Fulltext@MSK | Save

Characteristics of patients with relapsed and refractory low grade non-Hodgkin's lymphoma who sustained durable responses following treatment with tositumomab and iodine I 131 tositumomab (Bexxar (R))

Meeting Abstract

Gregory, S. A.; Kaminski, M. S.; Zelenetz, A. D.; Jain, V.
Blood (2002)

Fulltext@MSK | Save

2639 Results

People

Groups

Results (2639)

Meeting Abstract

Meeting Abstract

Meeting Abstract

Meeting Abstract

Meeting Abstract

Meeting Abstract

Meeting Abstract

Meeting Abstract

Meeting Abstract

Meeting Abstract